A Pilot Open-Label Trial of Use of the Glycine Transporter I Inhibitor, Sarcosine, in High-Functioning Children with Autistic Disorder
- *Corresponding Author:
- Chen-Lin Chang
100, Shin Chuan 1st Rd, Kaohsiung 807
Taiwan, Graduate Institute of Medicine
Kaohsiung Medical University and Kaohsiung Medical
University Hospital & Department of Psychiatry
Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan
E-mail: [email protected]
Received Date: April 01, 2014; Accepted Date: April 17, 2014; Published Date: April 22, 2014
Citation: Yang P, Lane HY, Yen CF, Chang CL (2014) A Pilot Open-Label Trial of Use of the Glycine Transporter I Inhibitor, Sarcosine, in High- Functioning Children with Autistic Disorder. Transl Med (Sunnyvale) 4:127. doi:10.4172/2161-1025.1000127
Copyright: © 2014 Yang P et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This open-label trial examined the efficacy and safety of a glycine transporter I inhibitor, sarcosine, in the 24-week treatment of high-functioning children with autistic disorder. Four children (three boys, one girl, 9-11 years of age; average intelligence quotient 80.5) completed the 24 weeks of study. Sarcosine administration was at 30 mg/kg/day in the form of a capsule in two divided doses. The outcome measures were. Autism Diagnostic Observation Schedule (Module 3), parent and teacher-reported Adaptive Behavior Assessment System-II, parenting stress index, Conners’ Continuous Performance Test, Wisconsin Card Sorting Test, child behavior checklist and Swanson, Nolan and Pelham IV hyperactivity attention scales. Safety assessments included monthly recorded vital signs, body weight, body height and adverse events. Statistical analysis found no significant treatment effect on all the outcome measures using the Wilcoxon Signed Rank test and generalized estimating equations analysis. However, an activation effect was reported by caregivers, and was corroborated by clinician’s observation. Details were reported as a case-series in the text. We concluded that sarcosine was well tolerated. Though the data are too preliminary to draw any definite conclusions about efficacy, they do suggest this therapy to be safe, and worthy of a double-blind placebo-controlled study with a focus on a certain subgroup of children with autism spectrum disorders.